Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

@article{Vesikari2006SafetyAE,
  title={Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.},
  author={Timo Vesikari and David O. Matson and Penelope H. Dennehy and Pierre van Damme and Mathuram Santosham and Zoe M Rodriguez and Michael J Dallas and Joseph F. Heyse and Michelle Gail Goveia and Steven B. Black and Henry R. Shinefield and Celia D. C. Christie and Samuli Ylitalo and Robbin F. Itzler and Michele L Coia and Matthew T. Onorato and Ben A Adeyi and Gary S. Marshall and Leif Gothefors and Dirk Campens and Aino V Karvonen and J. P. Watt and Katherine L. O'Brien and Mark J Dinubile and Hilary F. Clark and John W Boslego and Paul A. Offit and Penny M. Heaton},
  journal={The New England journal of medicine},
  year={2006},
  volume={354 1},
  pages={23-33}
}
BACKGROUND Rotavirus is a leading cause of childhood gastroenteritis and death worldwide. METHODS We studied healthy infants approximately 6 to 12 weeks old who were randomly assigned to receive three oral doses of live pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine containing human serotypes G1, G2, G3, G4, and P[8] or placebo at 4-to-10-week intervals in a blinded fashion. Active surveillance was used to identify subjects with serious adverse and other events. RESULTS… CONTINUE READING
Highly Influential
This paper has highly influenced 51 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 510 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 36 references

An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system : more than intussusception alone ?

  • J Joensuu, E Koskenniemi, XL Pang, T Vesikari
  • Pediatrics
  • 2004

Similar Papers

Loading similar papers…